Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Order Online! Now! Get your $50 coupon for online order. 
Order Online! Now! Get your $50 coupon for online order.
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one! Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers ! Time Limited Offer: Welcome Gift for New Customers !
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| DLL3 mAb - 01 | Lead | Solid Tumor | Small cell lung cancer |
5e5 of anti-DLL3 CAR-293 cells were stained with 100 μL of 1 μg/mL of Alexa Fluor 647-Labeled Human DLL3 Protein, His Tag (Cat. No. DL3-HA2H3) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). Alexa 647 signal was used to evaluate the binding activity (QC tested).
Immobilized Biotinylated Cynomolgus DLL3, His,Avitag (Cat. No. DL3-C82E9) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-DLL3 Antibody (specific Binding DSL of DLL3), Human IgG1 with a linear range of 0.1-1 ng/mL (QC tested).
The purity of Biotinylated Human DLL3, His,Avitag (Cat. No. DL3-H82E4) is more than 90% and the molecular weight of this protein is around 51-69 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Rovalpituzumab tesirine | SC-0002; SC0001SCX; SC16LD6.5; SC0001-SCX; P256HB60FF | Phase 1 Clinical | Stemcentrx Inc, Abbvie Inc | Solid tumours; Small Cell Lung Carcinoma; Glioblastoma; Neoplasms; Prostatic Neoplasms; Medullary thyroid cancer (MTC); Carcinoma, Neuroendocrine; Melanoma | Details |
| DLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital) | DLL3-CAR-NK cells | Phase 1 Clinical | Tianjin Medical University Cancer Institute And Hospital | Small Cell Lung Carcinoma | Details |
| OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | Details |
| 89Zr-DFO-SC16.56 | 89Zr-DFO-SC16.56 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Small Cell Lung Carcinoma | Details |
| QLS-31904 | QLS31904; QLS-31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| HPN-328 | HPN-328 | Phase 2 Clinical | Harpoon Therapeutics | Small Cell Lung Carcinoma | Details |
| BI-764532 | BI-764532 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Small Cell Lung Carcinoma; Neoplasms | Details |
| PT-217 | PT-217 | Phase 1 Clinical | Phanes Therapeutics Inc | Small Cell Lung Carcinoma; Pancreatic neuroendocrine tumors (pNET); Prostatic Neoplasms; Carcinoma, Neuroendocrine | Details |
| Tarlatamab | AMG-757 | Phase 2 Clinical | Amgen Inc | Small Cell Lung Carcinoma; Prostatic Neoplasms | Details |
| LB-2102(Legend Biotechnology) | LB-2102 | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Small Cell Lung Carcinoma; Neuroendocrine Tumors | Details |
This web search service is supported by Google Inc.
A-Z
